Qiagen Expands Companion Diagnostic Portfolio
Qiagen has received approval of its Therascreen EGFR Mutation Detection Kit RGQ from Japanese regulatory authorities.
The company said that the test can be used to personalize treatment for various cancer drug targeting EGFR. Qiagen characterized Japan has "one of the world’s largest markets for companion diagnostic tests."
The EGFR test marks Qiagen's second approval in Japan. In April 2011, Japanese health regulators approved Qiagen's Therascreen KRAS Mutation Detection Kit.